Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients
Wei-neng Feng, Wei-quan Gu, Ning Zhao, et al.

Super-ARMS and ddPCR share the similar accuracy for EGFR mutation detection in plasma biopsy; both methods predicted well the efficacy of EGFR-TKIs by detecting plasma EGFR status.

Translational Oncology (2018) 11, 542–545

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for frst-line geftinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
Zhijie Wang, Ying Cheng, Tongtong An, et al.

Detection of EGFR mutations in ctDNA is an effective method to identify patients who might beneft from frst-line geftinib treatment. Further analyses of dynamic alterations of EGFR mutations and accompanying gene aberrances could predict resistance to geftinib. Published online July 12, 2018

Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma
Shaohua Cui, Lin Ye, Huimin Wang, et al.

SuperARMS is a promising plasma-based assay for EGFR mutations, including T790M. It might be useful in advanced-stage lung adenocarcinoma patients whose tissue biopsy samples are insufficient for a traditional diagnostic EGFR assay or for patients with a poor performance status.

Clinical Lung Cancer, 2017.

Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment
Lucheng Zhu, Shirong Zhang, Yanping Xun, et al.

In conclusion, the results from this prospective study indicated the important clinical impact of T790 M detection using plasma samples for NSCLC patients who failed after EGFR-TKI therapy. Well concordance among three assays indicated the feasibility of plasma ctDNA detection. The ddPCR assay had a high sensitivity and might be superior to ARMS and SuperARMS assays.

Pathol. Oncol. Res., 2017. DOI 10.1007/s12253-017-0286-3

Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma
Yuping Li, Hanyan Xu, Shanshan Su, et al.

ADx-SuperARMS EGFR assay is likely to be a highly sensitive and specific method to noninvasively detect plasma EGFR mutations of patients with advanced lung adenocarcinoma. The EGFR mutations detected by ADx-SuperARMS EGFR assay could predict the efficacy of the treatment with first generation of EGFR-TKIs. Hence, EGFR blood testing with ADxSuperARMS could address the unmet clinical needs.

PLOS ONE, August 22, 2017.

Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR
Yan Wang, Yu Liu, Chao Zhao, et al.

Histological tissues are preferred for anaplastic lymphoma kinase(ALK)  fusion detection in non-small cell lung cancer(NSCLC). The aim of this study was to evaluate the feasibility of cytological sample as an alternative specimen for ALK fusion  testing in patients with advanced NSCLC. 

LUNG CANCER, DOI: 2016.01.014